Patient-reported Outcome: Recent Advances in Applications and Research at Home and Abroad

doi:10.12114/j.issn.1007-9572.2022.0805

Chinese General Practice ›› 2023, Vol. 26 ›› Issue (04): 401-408.DOI: 10.12114/j.issn.1007-9572.2022.0805

Special Issue: 患者报告结局最新文章合集

• Patient-reported Outcome • Previous Articles Next Articles

Patient-reported Outcome: Recent Advances in Applications and Research at Home and Abroad

1. Center for Health Management and Policy Research, School of Public Health, Cheeloo College of Medicine, Shandong University, Jinan 250012, China
2. NHC Key Lab of Health Economics and Policy Research (Shandong University) , Jinan 250012, China
3. Center for Health Preference Research, Shandong University, Jinan 250012, China
4. Center for Quality of Life and Public Policy Research, Shandong University, Jinan 250012, China

Received:2022-11-08 Revised:2022-12-01 Published:2023-02-05 Online:2022-12-08
Contact: LI Shunping
About author:
SHI Z, DOU L, LI S P. Patient-reported outcome: recent advances in applications and research at home and abroad[J]. Chinese General Practice, 2023, 26 (4) : 401-408.

国内外患者报告结局的应用现状与研究进展

1．250012　山东省济南市，山东大学齐鲁医学院公共卫生学院卫生管理与政策研究中心
2．250012　山东省济南市，国家卫生健康委员会卫生经济与政策研究重点实验室（山东大学）
3．250012　山东省济南市，山东大学健康偏好研究中心
4．250012　山东省济南市，山东大学生活质量与公共政策研究中心

通讯作者: 李顺平
作者简介:
史钊，窦蕾，李顺平.国内外患者报告结局的应用现状与研究进展[J].中国全科医学，2023，26（4）：401-408. [www.chinagp.net] 作者贡献：史钊、李顺平进行文章的构思与设计；史钊进行文献收集与整理；史钊、窦蕾、李顺平负责结果的分析与解释、论文撰写与修订；李顺平负责文章的可行性分析，并对文章整体负责，监督管理。
基金资助:
山东省自然科学基金面上项目(ZR2021MG010)

1. .png(599KB)

Abstract

Abstract:

Patient-reported outcome (PRO) refers to any information about the patient's own health condition, functional status, and feelings about treatment that directly comes from the patient without interpretation by physicians, nurses or anyone else. Measuring outcomes from the patient perspective is conducive to improving the quality of medical services and treatment satisfaction. We summarized recent applications of PRO in many fields, such as drug review and approval, drug and medical equipment supervision, quality evaluation of medical services, health technology assessment, and comprehensive clinical evaluation of drugs, and reviewed the latest advances in research on PRO, such as the development of PRO instruments, the construction of a health state utility value set, the health measurement in children and adolescents, and the quality evaluation of PRO instruments. Then we put forward recommendations to further promote the studies and use of PRO in China: strengthening the development of PRO instruments applicable to China, valuing the use of PRO in clinical practice, enhancing the interdisciplinary research on PRO, broadening the profile of research on PRO, and intensifying relevant research.

Key words: Patient-reported outcome, Clinical outcomes assessment, Health-related quality of life, Health outcomes

摘要：

患者报告结局（PRO）为直接来自患者报告的自身健康状况、功能状态及治疗感受等方面的信息，不包括医护人员及其他人员的解释。倾听来自患者的声音，有利于提高医疗服务质量与治疗满意度。本研究梳理了PRO在国内外药品审评审批与药械监管、医疗服务质量评价、卫生技术评估、药品临床综合评价等领域的应用现状，并且综述了近年来PRO量表研制、健康效用积分体系构建、儿童青少年健康测量、PRO测量工具的质量评价等国内外研究进展。最后建议未来应加强本土化PRO工具的研制与开发，重视PRO与临床实践相结合，同时应加强PRO研究学科间交叉及研究内容的深化，从而更好地促进我国PRO研究与应用的发展。

关键词: 患者报告结局, 临床结局评估, 健康相关生命质量, 健康结果

SHI Zhao,DOU Lei,LI Shunping. Patient-reported Outcome: Recent Advances in Applications and Research at Home and Abroad[J]. Chinese General Practice, 2023, 26(04): 401-408. DOI: 10.12114/j.issn.1007-9572.2022.0805.
史钊,窦蕾,李顺平. 国内外患者报告结局的应用现状与研究进展[J]. 中国全科医学, 2023, 26(04): 401-408. DOI: 10.12114/j.issn.1007-9572.2022.0805.

References 78

[1]	U.S. Food and Drug Administration（FDA）. Patient-focused drug development：collecting comprehensive and representative input[EB/OL]. [2022-10-25].
[2]	U.S. Food and Drug Administration（FDA）. Guidance for industry patient-reported outcome measures：use in medical product development to support labeling claims[EB/OL]. [2022-10-25].
[3]	刘砚燕，陈如男，姚静静，等. 患者报告结局的国内外研究进展[J]. 现代预防医学，2013，40(12):2268-2271.
[4]	隆莉芝，袁玲. 患者报告结局的应用近况及思考[J]. 中国全科医学，2020，23(32):4120-4127. DOI：10.12114/j.issn.1007-9572.2020.00.015.
[5]	ISHAQUE S, KARNON J, CHEN G, et al. A systematic review of randomised controlled trials evaluating the use of patient-reported outcome measures（PROMs）[J]. Qual Life Res，2019，28(3):567-592. DOI：10.1007/s11136-018-2016-z.
[6]	TORBJORN W, GUNHILD H, VIDA H, et al. Estimating QALY gains in applied studies：a review of cost-utility analyses published in 2010[J]. Pharmacoeconomics，2014，32(4):367-375. DOI：10.1007/s40273-014-0136-z.
[7]	KOVIC B, JIN X, KENNEDY S A, et al. Evaluating progression-free survival as a surrogate outcome for health-related quality of life in oncology：a systematic review and quantitative analysis[J]. JAMA Intern Med，2018，178(12):1586-1596. DOI：10.1001/jamainternmed.2018.4710.
[8]	闾承辰，薛爽，刘永军. 患者报告结局国内外应用进展对比研究[J]. 中国药物评价，2015，32(3):186-189. DOI：10.3969/j.issn.2095-3593.2015.03.019.
[9]	李文姣，程侣，王晗，等. 基于CiteSpaceⅤ软件的患者报告结局文献计量学分析[J]. 中国全科医学，2020，23(32):4128-4134. DOI：10.12114/j.issn.1007-9572.2020.00.317.
[10]	关宏峰，杨丽娜，杨悦. 美国患者报告结局测量工具在药物研发与注册中的应用[J]. 中国新药杂志，2022，31(2):142-146. DOI：10.3969/j.issn.1003-3734.2022.02.006.
[11]	吕宏梅，张岩波. 患者报告结局（PRO）在临床疗效评价体系中的应用与思考[J]. 医学与哲学（临床决策论坛版），2011，32(12):1-3.
[12]	European Medicines Agency（EMA）. Reflection paper on the regulatory guidance for the use of health related quality of life（HRQL） measures in the evaluation of medicinal products[EB/OL]. （2005-07-27）[2022-10-25].
[13]	U.S. Food and Drug Administration. Guidance for industry：patient-reported outcome measures：use in medical product development to support labeling claims：draft guidance[J]. Health Qual Life Outcomes，2006，4:79. DOI：10.1186/1477-7525-4-79.
[14]	DEMURO C, CLARK M, DOWARD L, et al. Assessment of PRO label claims granted by the FDA as compared to the EMA（2006—2010）[J]. Value Health，2013，16(8):1150-1155. DOI：10.1016/j.jval.2013.08.2293.
[15]	MESA R A, GOTLIB J, GUPTA V, et al. Effect of ruxolitinib therapy on myelofibrosis-related symptoms and other patient-reported outcomes in COMFORT-Ⅰ：a randomized，double-blind，placebo-controlled trial[J]. J Clin Oncol，2013，31(10):1285-1292. DOI：10.1200/JCO.2012.44.4489.
[16]	BASCH E. Toward patient-centered drug development in oncology[J]. N Engl J Med，2013，369(5):397-400. DOI：10.1056/NEJMp1114649.
[17]	GNANASAKTHY A, NORCROSS L, DEMURO R C, et al. A review of patient-reported outcome labeling of FDA-approved new drugs（2016—2020）：counts，categories，and comprehensibility[J]. Value Health，2022，25(4):647-655. DOI：10.1016/j.jval.2021.10.006.
[18]	BANSAL D, BHAGAT A, SCHIFANO F, et al. Role of patient-reported outcomes and other efficacy endpoints in the drug approval process in Europe（2008—2012）[J]. J Epidemiol Glob Health，2015，5(4):385-395. DOI：10.1016/j.jegh.2015.04.006.
[19]	U.S. Food and Drug Administration（FDA）. Qualified Clinical Outcome Assessments（COA）[EB/OL]. （2021-07-07）[2022-10-25].
[20]	PROMs Team, Health and Social Care. Provisional monthly patient reported outcome measures（PROMs） in England，Apr to Oct 2015[EB/OL]. （2016-03-10）[2022-10-25].
[21]	U.S. Food and Drug Administration（FDA）. Patient preference information-voluntary submission，review in premarket approval applications，humanitarian device exemption applications，and de novo requests，and inclusion in decision summaries and device labeling[EB/OL]. （2016-08-24）[2022-10-25].
[22]	COWIE L，BOUVY J，NICE. Measuring patient preferences：an exploratory study to determine how patient preferences data could be used in health technology assessment（HTA）[Z]. 2019.
[23]	KENNEDY-MARTIN M, SLAAP B, HERDMAN M, et al. Which multi-attribute utility instruments are recommended for use in cost-utility analysis? A review of national health technology assessment （HTA） guidelines[J]. Eur J Health Econ，2020，21(8):1245-1257. DOI：10.1007/s10198-020-01195-8.
[24]	李顺平，吴晶，陈钢. 多属性健康效用量表研制与应用述评[J]. 中国卫生经济，2020，39(10):5-8. DOI：10.7664/CHE20201001.
[25]	刘国恩，胡善联，吴晶，等. 中国药物经济学评价指南2020[M]. 北京：中国市场出版社，2020.
[26]	National Institutes of Health（NIH）. Patient-Reported Outcomes Measurement Information System（PROMIS） overview[EB/OL]. [2022-10-25].
[27]	刘砚燕，姚静静，陈如男，等. 患者报告结局测量信息系统（PROMIS）的研究进展[J]. 现代预防医学，2013，40(13):2440-2443.
[28]	DEWITT B, FEENY D, FISCHHOFF B, et al. Estimation of a preference-based summary score for the Patient-Reported Outcomes Measurement Information System：the PROMIS®-Preference（PROPr） scoring system[J]. Med Decis Making，2018，38(6):683-698. DOI：10.1177/0272989X18776637.
[29]	NORMAN R, OLSEN J A. Expanding the scope of value for economic evaluation：the EQ-HWB[J]. Value Health，2022，25(4):480-481. DOI：10.1016/j.jval.2022.02.001.
[30]	BRAZIER J, PEASGOOD T, MUKURIA C, et al. The EQ-HWB：overview of the development of a measure of health and wellbeing and key results[J]. Value Health，2022，25(4):482-491. DOI：10.1016/j.jval.2022.01.009.
[31]	PEASGOOD T, MUKURIA C, BRAZIER J, et al. Developing a new generic health and wellbeing measure：psychometric survey results for the EQ-HWB[J]. Value Health，2022，25(4):525-533. DOI：10.1016/j.jval.2021.11.1361.
[32]	陈亮江，沃田，陈磊，等. 儿童生存质量测量量表应用的文献分析[J]. 中国药房，2020，31(20):2539-2545. DOI：10.6039/j.issn.1001-0408.2020.20.19.
[33]	王江淋，陈钢，JULIE R，等. 儿童和青少年健康效用量表的研制和应用述评[J]. 中国卫生经济，2021，40(6):14-17.
[34]	SHIROIWA T, IKEDA S, NOTO S, et al. Valuation survey of EQ-5D-Y based on the international common protocol：development of a value set in Japan[J]. Med Decis Making，2021，41(5):597-606. DOI：10.1177/0272989X211001859.
[35]	PREVOLNIK R V, OGOREVC M. EQ-5D-Y value set for slovenia[J]. Pharmacoeconomics，2021，39(4):463-471. DOI：10.1007/s40273-020-00994-4.
[36]	RAMOS-GONI J M, OPPE M, ESTEVEZ-CARRILLO A, et al. Accounting for unobservable preference heterogeneity and evaluating alternative anchoring approaches to estimate country-specific EQ-5D-Y value sets：a case study using spanish preference data[J]. Value Health，2022，25(5):835-843. DOI：10.1016/j.jval.2021.10.013.
[37]	KREIMEIER S, MOTT D, LUDWIG K, et al. EQ-5D-Y value set for Germany[J]. Pharmacoeconomics，2022，40(Suppl 2):s217-229. DOI：10.1007/s40273-022-01143-9.
[38]	张雯，黄青梅，黄跃师，等. 患者报告结局测量工具质量评价标准的研究进展[J]. 护士进修杂志，2020，35(20):1825-1830. DOI：10.16821/j.cnki.hsjx.2020.26.004.
[39]	PRINSEN C, MOKKINK L B, BOUTER L M, et al. COSMIN guideline for systematic reviews of patient-reported outcome measures[J]. Qual Life Res，2018，27(5):1147-1157. DOI：10.1007/s11136-018-1798-3.
[40]	MOKKINK L B, DE VET H, PRINSEN C, et al. COSMIN risk of bias checklist for systematic reviews of patient-reported outcome measures[J]. Qual Life Res，2018，27(5):1171-1179. DOI：10.1007/s11136-017-1765-4.
[41]	张璐嘉，李顺平. COSMIN系统综述指南应用简介[J]. 中国药物经济学，2020，15(1):5-7. DOI：10.12010/j.issn.1673-5846.2020.01.001.
[42]	国家药品监督管理局. 真实世界证据支持药物研发与审评的指导原则（试行）[EB/OL]. （2020-01-07）[2022-10-25].
[43]	国家药品监督管理局药品审评中心. 用于产生真实世界证据的真实世界数据指导原则（试行）[EB/OL]. （2021-04-15） [2022-10-25].
[44]	国家药品监督管理局药品审评中心. 以临床价值为导向的抗肿瘤药物临床研发指导原则[EB/OL]. （2021-11-19） [2022-10-25].
[45]	国家药品监督管理局药品审评中心. 罕见疾病药物临床研发技术指导原则[EB/OL]. （2022-01-06）[2022-10-25].
[46]	国家药品监督管理局药品审评中心. 患者报告结局在药物临床研发中应用的指导原则（试行）[EB/OL]. （2022-01-04） [2022-10-25].
[47]	国家药品监督管理局药品审评中心. 关于公开征求《以患者为中心的临床试验获益-风险评估技术指导原则（征求意见稿）》意见的通知[EB/OL]. （2022-08-09）[2022-10-25].
[48]	国家药品监督管理局药品审评中心. 关于公开征求《以患者为中心的临床试验设计技术指导原则（征求意见稿）》意见的通知[EB/OL]. （2022-08-09）[2022-10-25].
[49]	国家药品监督管理局药品审评中心. 关于公开征求《以患者为中心的临床试验实施技术指导原则》（征求意见稿）意见的通知[EB/OL]. （2022-08-09）[2022-10-25].
[50]	ZHOU H, YAO M, GU X, et al. Application of patient-reported outcome measurements in clinical trials in China[J]. JAMA Netw Open，2022，5(5):e2211644. DOI：10.1001/jamanetworkopen.
[51]	国家医疗保障局. 基本医疗保险用药管理暂行办法[EB/OL]. （2020-07-30）[2022-10-25].
[52]	国家卫生健康委员会. 国家卫生健康委办公厅关于规范开展药品临床综合评价工作的通知[EB/OL]. （2021-07-28）[2022-10-25].
[53]	万崇华，陈明清，张灿珍，等. 癌症患者生命质量测定量表EORTC QLQ-C30中文版评介[J]. 实用肿瘤杂志，2005，20(4):353-355. DOI：10.3969/j.issn.1001-1692.2005.04.028.
[54]	JIN X, LIU G G, GERSTEIN H C, et al. Item reduction and validation of the Chinese version of Diabetes Quality-of-life Measure（DQOL）[J]. Health Qual Life Outcomes，2018，16(1):78. DOI：10.1186/s12955-018-0905-z.
[55]	TANG C, XIONG Y, WU H, et al. Adaptation and assessments of the Chinese version of the ICECAP-A measurement[J]. Health Qual Life Outcomes，2018，16(1):45. DOI：10.1186/s12955-018-0865-3.
[56]	陈晴，李顺平，唐程翔，等. 可行能力生命质量量表的应用介绍[J]. 中国卫生经济，2020，39(8):9-12. DOI：10.7664/CHE20200802.
[57]	WU J, XIE S, HE X, et al. The simplified Chinese version of SF-6Dv2：translation，cross-cultural adaptation and preliminary psychometric testing[J]. Qual Life Res，2020，29(5):1385-1391. DOI：10.1007/s11136-020-02419-3.
[58]	万崇华，杨铮，吴婷，等. 癌症患者生命质量测定量表体系的测量学特性与应用[J]. 中华行为医学与脑科学杂志，2020，29(3):277-278. DOI：10.3760/cma.j.cn371468-20190827-00557.
[59]	万崇华. 癌症患者生命质量测定量表体系第2版QLICP（V2.0）研究现状[J]. 广东医科大学学报，2020，38(5):511-517. DOI：10.3969/j.issn.1005-4057.2020.05.001.
[60]	万崇华，张晓磬，李晓梅，等. 慢性病患者生命质量测定量表体系QLICD各量表的测量学特性分析[J]. 昆明医学院学报，2009，30(8):40-45. DOI：10.3969/j.issn.1003-4706.2009.08.009.
[61]	ZHU L, KONG J, ZHENG Y, et al. Development and initial validation of the Chronic Hepatitis B Quality of Life Instrument（CHBQOL） among Chinese patients[J]. Qual Life Res，2019，28(11):3071-3081. DOI：10.1007/s11136-019-02240-7.
[62]	于长禾，孙亚男，何丽云，等. 中医生活质量量表心理测量性能证据的系统评价[J]. 中华中医药杂志，2015，30(5):1631-1635.
[63]	SHI Z, MAO Z, NIE H, et al. Development and validation of the Health-related Quality of Life Instrument for Chinese Infertile Couples：a mixed-methods study protocol[J]. Health Qual Life Outcomes，2022，20(1):54. DOI：10.1186/s12955-022-01957-3.
[64]	LIU G G, WU H, LI M, et al. Chinese time trade-off values for EQ-5D health states[J]. Value Health，2014，17(5):597-604. DOI：10.1016/j.jval.2014.05.007.
[65]	ZHUO L, XU L, YE J, et al. Time trade-off value set for EQ-5D-3L based on a nationally representative Chinese population survey[J]. Value Health，2018，21(11):1330-1337. DOI：10.1016/j.jval.2018.04.1370.
[66]	LIU G, GUAN H, JIN X, et al. Rural population's preferences matter：a value set for the EQ-5D-3L health states for China's rural population[J]. Health Qual Life Outcomes，2022，20(1):14. DOI：10.1186/s12955-022-01917-x.
[67]	LUO N, LIU G, LI M, et al. Estimating an EQ-5D-5L value set for China[J]. Value Health，2017，20(4):662-669. DOI：10.1016/j.jval.2016.11.016.
[68]	WU J, XIE S, HE X, et al. Valuation of SF-6Dv2 health states in China using time trade-off and discrete-choice experiment with a duration dimension[J]. Pharmacoeconomics，2021，39(5):521-535. DOI：10.1007/s40273-020-00997-1.
[69]	CHEN G, XU F, HUYNH E, et al. Scoring the Child Health Utility 9D Instrument：estimation of a Chinese child and adolescent-specific tariff[J]. Qual Life Res，2019，28(1):163-176. DOI：10.1007/s11136-018-2032-z.
[70]	傅卫，赵琨. 中国卫生技术评估的发展与挑战[J]. 卫生经济研究，2019，36(3):3-5. DOI：10.14055/j.cnki.33-1056/f.2019.03.001.
[71]	朱文涛，高海亮，张梦培，等. 中医生命质量评价量表（CQ-11D）的研制[J]. 中国药物经济学，2022，17(5):10-15. DOI：10.12010/j.issn.1673-5846.2022.05.002.
[72]	朱文涛，高海亮，张梦培，等. 中医生命质量评价量表（CQ-11D）解读[J]. 中国药物经济学，2022，17(5):16-20. DOI：10.12010/j.issn.1673-5846.2022.05.003.
[73]	李丹钰，黄青梅，吴傅蕾，等. 基于工作流理念的患者报告结局测量系统中国中心（PNC-China）信息化管理系统的构建[J]. 上海护理，2021，21(7):5-9. DOI：10.3969/j.issn.1009-8399.2021.07.002.
[74]	MAO Z, AHMED S, GRAHAM C, et al. Similarities and differences in health-related quality-of-life concepts between the east and the west：a qualitative analysis of the content of health-related quality-of-life measures[J]. Value Health Reg Issues，2021，24:96-106. DOI：10.1016/j.vhri.2020.11.007.
[75]	MAO Z, AHMED S, GRAHAM C, et al. Exploring subjective constructions of health in China：a Q-methodological investigation[J]. Health Qual Life Outcomes，2020，18(1):165. DOI：10.1186/s12955-020-01414-z.
[76]	DAI W, FENG W, ZHANG Y, et al. Patient-reported outcome-based symptom management versus usual care after lung cancer surgery：a multicenter randomized controlled trial[J]. J Clin Oncol，2022，40(9):988-996. DOI：10.1200/JCO.21.01344.
[77]	张雯，黄青梅，黄跃师，等. 患者报告结局测量信息系统电子化数据收集工具的研究与发展现状[J]. 护士进修杂志，2021，36(4):289-293.
[78]	李小贤，赵烨，林峰，等. 电子化患者报告结局在新药临床试验疗效评价中的应用[J]. 药物评价研究，2021，44(5):909-916. DOI：10.7501/j.issn.1674-6376.2021.05.001.

Patient-reported Outcome: Recent Advances in Applications and Research at Home and Abroad

国内外患者报告结局的应用现状与研究进展

RichHTML

PDF

Supplement

Knowledge

Abstract

Cite this article

share this article

References 78

Related Articles 15

Recommended Articles

Metrics

Comments

[1]	TIAN Wei, TAO Mengmeng, LI Kunkun, CAO Wenjun, HOU Guoqiang. Health-related Quality of Life and Its Influencing Factors among Elderly Patients with Multimorbidity in China [J]. Chinese General Practice, 2024, 27(11): 1303-1309.
[2]	XU Huijing, WU Shanyu, JIANG Jiawei, WU Yuanhong, WANG Xiaohui, GAO Ge, WANG Zhe, WANG Yuyu. Translation of the Patient-reported Outcomes Measure of Pharmaceutical Therapy for Quality of Life and Its Validation in Elderly Patients with Polypharmacy [J]. Chinese General Practice, 2024, 27(05): 612-621.
[3]	GAO Jing, ZHOU Shangcheng, GAO Sande, ZOU Guanyang, CHEN Yingyao. Health-related Quality of Life and Its Influencing Factors in Patients with Prevention of Disease in Traditionnal Chinese Medicine based on EQ-5D-5L Scale [J]. Chinese General Practice, 2023, 26(32): 4043-4050.
[4]	WEI Mengyu, WANG Jiajia, ZHANG Yingying, LI Chunyang, LI Jiansheng. Research Status of Patient-reported Outcome Assessment Tools for Obstructive Sleep Apnea [J]. Chinese General Practice, 2023, 26(30): 3725-3733.
[5]	LI Peiwen, HE Jiahui, MA Ximin, QIAO Hui. Health-related Quality of Life Measured Using the EQ-5D-3L and Health Service Utilization in Rural Residents of Ningxia [J]. Chinese General Practice, 2023, 26(19): 2361-2368.
[6]	ZHOU Hui, LIN Ying, ZHOU Guojin, TANG Kejing, YUAN Gang, YAO Mi. Interpretation of Ethical Considerations for the Inclusion of Patient-Reported Outcomes in Clinical Research (the PRO Ethics Guidelines) [J]. Chinese General Practice, 2023, 26(04): 395-400.
[7]	Jianfeng LUO, Jiangtao HOU, Zhengkun HOU, Bin PENG, Huibiao LI, Shiying LIU, Zhenfan HE, Jiamin ZHONG, Shijing ZHANG, Fengbin LIU, Xinlin CHEN. Development and Item Selection of the Inflammatory Bowel Disease Patient-reported Outcomes Scale Based on Theories of Traditional Chinese Medicine [J]. Chinese General Practice, 2022, 25(29): 3672-3677.
[8]	Zhao SHI, Shunping LI, Xiaoyan WU, Jiaqi LIU, Huimin DU. Health-related Quality of Life Instruments in Infertility Patients: a Systematic Review and Evaluation [J]. Chinese General Practice, 2022, 25(28): 3579-3586.
[9]	Wenqiong LIU, Yanbo ZHU, Fanghui MA, Xinrui WU, Yueheng LOU, Xinyuan ZHAO, Yuqiong LI, Liqun LONG, Pipi CHEN. Mediating Effect of Exercise on the Relationship between Biased Constitution and Health-related Quality of Life [J]. Chinese General Practice, 2022, 25(27): 3372-3378.
[10]	Yue ZENG, Yue DU. Health-related Quality of Life in Children with Nephrotic Syndrome [J]. Chinese General Practice, 2022, 25(27): 3379-3383.
[11]	ZHAO Tiefu，WANG Shengyu，ZHANG Chunxiao，ZHANG Ming，CHEN Hong，MA Hanying. Health-related Quality of Life of Middle-aged Patients with Exercise Intervention after Off-pump Coronary Artery Bypass Grafting　 [J]. Chinese General Practice, 2021, 24(14): 1752-1757.
[12]	CHEN Xia，LIU Fangli，LI Rui，WANG Ying. Systematic Review of Factors Influencing Oral Health-related Quality of Life in School-age Children　 [J]. Chinese General Practice, 2021, 24(1): 118-124.
[13]	LI Bin，HUANG Yizhou，JIA Yingxian，MA Linjuan，YING Qian，ZHOU Jianhong. Common Scales about Health-related Quality of Life among Menopausal Women and Their Application　 [J]. Chinese General Practice, 2020, 23(34): 4400-4404，4406.
[14]	LONG Lizhi，YUAN Ling. The Application and Consideration of Patient-reported Outcomes　 [J]. Chinese General Practice, 2020, 23(32): 4120-4127.
[15]	LI Wenjiao，CHENG Lyu，WANG Han，NING Yun，JIN Changde，LI Yan. Bibliometric Analysis of Patient-reported Outcomes Using CiteSpaceⅤ　 [J]. Chinese General Practice, 2020, 23(32): 4128-4134.